To evaluate the potential therapeutic effects of GPR4 antagonists in COVID-19, the inhibitors can first be tested in preclinical animal models predisposed to infection with SARS-CoV-2, such as the human angiotensin-converting enzyme 2 (hACE2) transgenic mice and hamsters (59, 60). Here, GPR4 is linked to infection.